BDRX

Biodexa Pharmaceuticals Plc BDRX

NasdaqMega CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-6.38M

Quarter to Dec 31

Free cash flow

$-5.59M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$48.1K total
ARMISTICE CAPITAL, LLC
$43.1K-84.8%
GAMMA Investing LLC
$3.5K-91.3%
Allied Private Wealth LLC
$1.3K--
SBI Securities Co., Ltd.
$84-80.8%
UBS Group AG
$73-80.3%
Hilton Head Capital Partners, LLC
$17-80.0%
Caitong International Asset Management Co., Ltd
$15+400.0%
RHUMBLINE ADVISERS
$8-84.2%
See all 8 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

BDRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Biodexa Pharmaceuticals Plc's annual filings on SEC EDGAR.

Biodexa Pharmaceuticals Plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$381.0K$-7.1M—
FY 2022$699.0K$-7.7M—
FY 2021$578.0K$-5.5M—
FY 2020$343.0K$-22.2M—
FY 2019$674.0K$-10.1M—
FY 2018$1.9M$-15.0M—
Source: BDRX filings on SEC EDGAR →

About Biodexa Pharmaceuticals Plc (BDRX): stock profile, AI score and financials

Biodexa Pharmaceuticals Plc (BDRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BDRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Biodexa Pharmaceuticals Plc reports net income of $-6.4M, free cash flow of $-5.6M. Top institutional holders of BDRX by reported 13-F value include ARMISTICE CAPITAL, GAMMA Investing, Allied Private Wealth, based on the most recent SEC filings. BDRX trades on the Nasdaq exchange and files with the SEC under CIK 1643918. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biodexa Pharmaceuticals Plc directly from SEC EDGAR.

SEC EDGAR: CIK 1643918 →